{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:43:18Z","timestamp":1792633398591,"version":"4.5.0"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec id=\"ab-noi240034-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Animal and human studies have suggested that the use of angiotensin receptor blockers (ARBs) may be associated with a lower risk of incident epilepsy compared with other antihypertensive medications. However, observational data from the US are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240034-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between ARB use and epilepsy incidence in subgroups of US patients with hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240034-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective cohort study used data from a national health administrative database from January 2010 to December 2017 with propensity score (PS) matching. The eligible cohort included privately insured individuals aged 18 years or older with diagnosis of primary hypertension and dispensed at least 1 ARB, angiotensin-converting enzyme inhibitor (ACEI), \u03b2-blocker, or calcium channel blocker (CCB) from 2010 to 2017. Patients with a diagnosis of epilepsy at or before the index date or dispensed an antiseizure medication 12 months before or 90 days after initiating the study medications were excluded. The data analysis for this project was conducted from April 2022 to April 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240034-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Propensity scores were generated based on baseline covariates and used to match patients who received ARBs with those who received either ACEIs, \u03b2-blockers, CCBs, or a combination of these antihypertensive medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240034-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Cox regression analyses were used to evaluate epilepsy incidence during follow-up comparing the ARB cohort with other antihypertensive classes. Subgroup and sensitivity analyses were conducted to examine the association between ARB use and epilepsy incidence in various subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240034-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2\u202f261\u202f964 patients (mean [SD] age, 61.7 [13.9] years; 1\u202f120\u202f630 [49.5%] female) included, 309\u202f978 received ARBs, 807\u202f510 received ACEIs, 695\u202f887 received \u03b2-blockers, and 448\u202f589 received CCBs. Demographic and clinical characteristics differed across the 4 comparison groups prior to PS matching. Compared with ARB users, patients receiving ACEIs were predominantly male and had diabetes, CCB users were generally older (eg, &amp;amp;gt;65 years), and \u03b2-blocker users had more comorbidities and concurrent medications. The 1:1 PS-matched subgroups included 619\u202f858 patients for ARB vs ACEI, 619\u202f828 patients for ARB vs \u03b2-blocker, and 601\u202f002 patients for ARB vs CCB. Baseline characteristics were equally distributed between comparison groups after matching with propensity scores. Use of ARBs was associated with a decreased incidence of epilepsy compared with ACEIs (adjusted hazard ratio [aHR], 0.75; 95% CI, 0.58-0.96), \u03b2-blockers (aHR, 0.70; 95% CI, 0.54-0.90), and a combination of other antihypertensive classes (aHR, 0.72; 95% CI, 0.56-0.95). Subgroup analyses revealed a significant association between ARB use (primarily losartan) and epilepsy incidence in patients with no preexisting history of stroke or cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240034-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This cohort study found that ARBs, mainly losartan, were associated with a lower incidence of epilepsy compared with other antihypertensive agents in hypertensive patients with no preexisting stroke or cardiovascular disease. Further studies, such as randomized clinical trials, are warranted to confirm the comparative antiepileptogenic properties of antihypertensive medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.1714","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:32:32Z","timestamp":1718623952000},"page":"866","source":"Crossref","is-referenced-by-count":26,"title":["Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy"],"prefix":"10.1001","volume":"81","author":[{"given":"Xuerong","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne N.","family":"Otoo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Brothers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina E.","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Asal","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimford J.","family":"Meador","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"noi240034r1","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","article-title":"Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010.","volume":"126","author":"Gu","year":"2012","journal-title":"Circulation"},{"issue":"14","key":"noi240034r2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.15585\/mmwr.mm6914a1","article-title":"Prevalence of self-reported hypertension and antihypertensive medication use among adults\u2014United States, 2017.","volume":"69","author":"Samanic","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"noi240034r3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1042\/CS20100053","article-title":"Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy.","volume":"119","author":"Pereira","year":"2010","journal-title":"Clin Sci (Lond)"},{"issue":"12","key":"noi240034r4","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1586\/14737175.2014.972945","article-title":"Should losartan be administered following brain injury?","volume":"14","author":"Friedman","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"noi240034r5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.brainresbull.2019.05.002","article-title":"Losartan inhibits development of spontaneous recurrent seizures by preventing astrocyte activation and attenuating blood-brain barrier permeability following pilocarpine-induced status epilepticus.","volume":"149","author":"Hong","year":"2019","journal-title":"Brain Res Bull"},{"issue":"6","key":"noi240034r6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/ana.v75.6","article-title":"Losartan prevents acquired epilepsy via TGF-\u00df signaling suppression.","volume":"75","author":"Bar-Klein","year":"2014","journal-title":"Ann Neurol"},{"issue":"6","key":"noi240034r7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10571-015-0278-3","article-title":"Long-term treatment with losartan attenuates seizure activity and neuronal damage without affecting behavioral changes in a model of co-morbid hypertension and epilepsy.","volume":"36","author":"Tchekalarova","year":"2016","journal-title":"Cell Mol Neurobiol"},{"issue":"3","key":"noi240034r8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/epi.v61.3","article-title":"Repurposed molecules for antiepileptogenesis: missing an opportunity to prevent epilepsy?","volume":"61","author":"Klein","year":"2020","journal-title":"Epilepsia"},{"issue":"12","key":"noi240034r9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1001\/jamaneurol.2022.3413","article-title":"Association between angiotensin receptor blocker therapy and incidence of epilepsy in patients with hypertension.","volume":"79","author":"Doege","year":"2022","journal-title":"JAMA Neurol"},{"issue":"5","key":"noi240034r10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/jamaneurol.2023.0404","article-title":"Association between use of angiotensin receptor blockers and incidence of epilepsy in patients with hypertension.","volume":"80","author":"Ryu","year":"2023","journal-title":"JAMA Neurol"},{"issue":"5","key":"noi240034r11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/jamaneurol.2023.0407","article-title":"Association between use of angiotensin receptor blockers and incidence of epilepsy in patients with hypertension-reply.","volume":"80","author":"Doege","year":"2023","journal-title":"JAMA Neurol"},{"issue":"24","key":"noi240034r12","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data.","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"noi240034r13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"9","key":"noi240034r14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"7_supplement","key":"noi240034r15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.80.7_supplement.P05.247","article-title":"How reliable are the ICD9-CM billing codes in the administrative data to estimate the risk of seizures and epilepsy after stroke?","volume":"80","author":"Jesus-Alvelo","year":"2013","journal-title":"Neurology"},{"key":"noi240034r16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.eplepsyres.2016.09.012","article-title":"Implementation of an established algorithm and modifications for the identification of epilepsy patients in the veterans health administration.","volume":"127","author":"Rehman","year":"2016","journal-title":"Epilepsy Res"},{"issue":"1","key":"noi240034r17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/epi.v63.1","article-title":"Vascular risk factors as predictors of epilepsy in older age: The Framingham Heart Study.","volume":"63","author":"Stefanidou","year":"2022","journal-title":"Epilepsia"},{"issue":"1","key":"noi240034r18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ene.2019.26.issue-1","article-title":"Stroke-related epilepsy.","volume":"26","author":"Feyissa","year":"2019","journal-title":"Eur J Neurol"},{"issue":"10","key":"noi240034r19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2165\/00002512-200421100-00003","article-title":"Poststroke epilepsy: epidemiology, pathophysiology and management.","volume":"21","author":"Ferro","year":"2004","journal-title":"Drugs Aging"},{"key":"noi240034r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109102","article-title":"Antidepressant drugs use and epilepsy risk: a nationwide nested case-control study.","volume":"140","author":"Chu","year":"2023","journal-title":"Epilepsy Behav"},{"issue":"1","key":"noi240034r21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1684\/epd2.v24.1","article-title":"Prevalence of various risk factors associated with new-onset epilepsy after the age of 50: a retrospective population-based study.","volume":"24","author":"Cvetkovska","year":"2022","journal-title":"Epileptic Disord"},{"key":"noi240034r22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.yebeh.2018.10.035","article-title":"Incidence of epilepsy and associated factors in elderly patients in Germany.","volume":"90","author":"Jacob","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"10225","key":"noi240034r23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(19)33064-8","article-title":"Epilepsy in older people.","volume":"395","author":"Sen","year":"2020","journal-title":"Lancet"},{"key":"noi240034r24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/bs.irn.2022.06.012","article-title":"Sex and gender differences in epilepsy.","volume":"164","author":"Hophing","year":"2022","journal-title":"Int Rev Neurobiol"},{"issue":"9","key":"noi240034r25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/archneurol.2011.3647","article-title":"Atrial fibrillation associated with epileptic seizures.","volume":"69","author":"Herskovitz","year":"2012","journal-title":"Arch Neurol"},{"issue":"7","key":"noi240034r26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41582-023-00826-x","article-title":"Cardiovascular risk factors for epilepsy and dementia.","volume":"19","author":"Romoli","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"noi240034r27","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1177\/0962280213519716","article-title":"The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study.","volume":"25","author":"Austin","year":"2016","journal-title":"Stat Methods Med Res"},{"key":"noi240034r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.135753","article-title":"Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis.","volume":"750","author":"Reddy","year":"2021","journal-title":"Neurosci Lett"},{"key":"noi240034r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108721","article-title":"Atrial fibrillation is associated with a subsequent epilepsy diagnosis independent of stroke: a retrospective matched administrative cohort study on 149,632 patients.","volume":"132","author":"Doege","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"10","key":"noi240034r30","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.05.044","article-title":"The association between atrial fibrillation and poststroke seizures is influenced by ethnicity and environmental factors.","volume":"27","author":"Naylor","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"11","key":"noi240034r31","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/jamaneurol.2020.2499","article-title":"Trends in antihypertensive medication use among individuals with a history of stroke and hypertension, 2005 to 2016.","volume":"77","author":"Santos","year":"2020","journal-title":"JAMA Neurol"},{"issue":"5","key":"noi240034r32","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad087","article-title":"In atrial fibrillation epilepsy risk differs between oral anticoagulants: active comparator, nested case-control study.","volume":"25","author":"Platzbecker","year":"2023","journal-title":"Europace"},{"issue":"9","key":"noi240034r33","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1111\/epi.v62.9","article-title":"Understanding cardiovascular disease in older adults with epilepsy.","volume":"62","author":"Husein","year":"2021","journal-title":"Epilepsia"},{"issue":"19","key":"noi240034r34","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.jacc.2022.03.337","article-title":"The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review.","volume":"79","author":"Camm","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"noi240034r35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/aje\/kwu122","article-title":"Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy.","volume":"181","author":"Cole","year":"2015","journal-title":"Am J Epidemiol"},{"issue":"3","key":"noi240034r36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/15357597231160607","article-title":"Anti-Epileptogenesis: Some Roads Lead to Losartan.","volume":"23","author":"Sarkis","year":"2023","journal-title":"Epilepsy Curr"},{"issue":"1-3","key":"noi240034r37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejphar.2010.04.053","article-title":"Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.","volume":"640","author":"Lukawski","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"noi240034r38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.neuroscience.2014.07.058","article-title":"Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction.","volume":"277","author":"Lenz","year":"2014","journal-title":"Neuroscience"},{"issue":"36","key":"noi240034r39","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1523\/JNEUROSCI.1751-04.2004","article-title":"Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex.","volume":"24","author":"Seiffert","year":"2004","journal-title":"J Neurosci"},{"issue":"4","key":"noi240034r40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/epi.2007.48.issue-4","article-title":"Seizure-promoting effect of blood-brain barrier disruption.","volume":"48","author":"Marchi","year":"2007","journal-title":"Epilepsia"},{"issue":"1","key":"noi240034r41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.brainres.2006.02.068","article-title":"In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: insights into the mechanisms of pharmacoresistance.","volume":"1086","author":"Oby","year":"2006","journal-title":"Brain Res"},{"issue":"9","key":"noi240034r42","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135391","article-title":"Reactive astrocyte-driven epileptogenesis is induced by microglia initially activated following status epilepticus.","volume":"6","author":"Sano","year":"2021","journal-title":"JCI Insight"},{"issue":"6","key":"noi240034r43","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1097\/00004872-199715066-00007","article-title":"Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.","volume":"15","author":"Weber","year":"1997","journal-title":"J Hypertens Suppl"},{"key":"noi240034r44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/OAEM","article-title":"ACE inhibitors\u2014angiotensin II receptor antagonists: a useful combination therapy for ischemic heart disease.","volume":"2","author":"Saleem","year":"2010","journal-title":"Open Access Emerg Med"},{"issue":"6","key":"noi240034r45","first-page":"351","article-title":"Beta-blockers and the treatment of hypertension: it is time to move on.","volume":"18","author":"Wiysonge","year":"2007","journal-title":"Cardiovasc J Afr"},{"issue":"5","key":"noi240034r46","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.cjca.2014.02.012","article-title":"\u00df-Blockers in hypertension: studies and meta-analyses over the years.","volume":"30","author":"Larochelle","year":"2014","journal-title":"Can J Cardiol"},{"issue":"7","key":"noi240034r47","first-page":"503","article-title":"JNC8 guidelines for the management of hypertension in adults.","volume":"90","author":"Armstrong","year":"2014","journal-title":"Am Fam Physician"},{"issue":"19","key":"noi240034r48","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"noi240034r49","first-page":"1023","article-title":"AHA\/ACC\/ASH release guideline on the treatment of hypertension and CAD.","volume":"92","author":"Randel","year":"2015","journal-title":"Am Fam Physician"},{"issue":"2","key":"noi240034r51","first-page":"270","article-title":"AHA releases guidelines for hypertension management in adults with or at risk of CAD.","volume":"78","author":"Huntzinger","year":"2008","journal-title":"Am Fam Physician"},{"issue":"2","key":"noi240034r52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0165-0327(87)90017-6","article-title":"Beta-blockers in anxiety disorders.","volume":"13","author":"Hayes","year":"1987","journal-title":"J Affect Disord"},{"issue":"2","key":"noi240034r53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis.","volume":"30","author":"Steenen","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"48","key":"noi240034r55","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013152","article-title":"Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: a systematic review and meta-analysis.","volume":"97","author":"Lin","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"noi240034r56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/00129784-200707001-00003","article-title":"Calcium channel blockers: differences between subclasses.","volume":"7","author":"Frishman","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"noi240034r57","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.seizure.2016.10.001","article-title":"The heart of epilepsy: current views and future concepts.","volume":"44","author":"Shmuely","year":"2017","journal-title":"Seizure"},{"key":"noi240034r58","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107878","article-title":"Cardiovascular disease risk, awareness, and treatment in people with epilepsy.","volume":"117","author":"Terman","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"2","key":"noi240034r59","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.amjmed.2019.08.055","article-title":"Propensity score matching: the \u2018devil is in the details\u2019 where more may be hidden than you know.","volume":"133","author":"Reiffel","year":"2020","journal-title":"Am J Med"},{"issue":"6","key":"noi240034r60","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/ejcts\/ezy167","article-title":"Statistical primer: propensity score matching and its alternatives.","volume":"53","author":"Benedetto","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"noi240034r54","volume-title":"StatPearls","author":"McKeever","year":"2023"},{"key":"noi240034r50","unstructured":"Mann? JFE, Flack? JM. Choice of drug therapy in primary (essential) hypertension. UpToDate. March 28, 2024. Accessed August 10, 2023. https:\/\/www.uptodate.com\/contents\/choice-of-drug-therapy-in-primary-essential-hypertension"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2820196\/jamaneurology_wen_2024_oi_240034_1723221547.86614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:01:56Z","timestamp":1723460516000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2820196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.1714","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}